- 全部删除
您的购物车当前为空
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor) 是一种 Eph 受体酪氨酸激酶抑制剂,可用于治疗癌症。


为众多的药物研发团队赋能,
让新药发现更简单!
ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor) 是一种 Eph 受体酪氨酸激酶抑制剂,可用于治疗癌症。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 760 | In stock | |
| 5 mg | ¥ 1,570 | In stock | |
| 10 mg | ¥ 2,390 | In stock | |
| 25 mg | ¥ 3,960 | In stock | |
| 50 mg | ¥ 5,770 | In stock | |
| 100 mg | ¥ 7,790 | In stock | |
| 200 mg | ¥ 10,500 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 2,080 | In stock |
ALW-II-41-27 相关产品
| 产品描述 | ALW-II-41-27 (Eph receptor tyrosine kinase inhibitor), an Eph receptor tyrosine kinase inhibitor, is used for cancer therapy. |
| 靶点活性 | Eph family tyrosine kinase:11 nM |
| 体外活性 | ALW-II-41-27抑制通过Tel融合的Kit、EphA3、Fms、KDR、FLT1、FGR、Src、Bmx、Lyn和Bcr-Abl转化的Ba/F3细胞(EC50<500 nM),且对Bcr-Abl有交叉反应性。ALW-II-41-27还能抑制b-Raf、CSF1R、DDR1、DDR2、EphA2、EphA8、EphB1、EphB2、Kit、EphB3、Frk、Lck、EphA5、p38α、p38β、PDGFRβ、PDGFRα及Raf1。 |
| 别名 | Eph receptor tyrosine kinase inhibitor |
| 分子量 | 607.69 |
| 分子式 | C32H32F3N5O2S |
| CAS No. | 1186206-79-0 |
| Smiles | CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(NC(=O)c4cncc(c4)-c4cccs4)c3)cc2C(F)(F)F)CC1 |
| 密度 | 1.321 g/cm3 (Predicted) |
| 颜色 | Yellow |
| 物理性状 | Solid |
| 存储 | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 55 mg/mL (90.51 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容